General information
Simmons & Simmons LLP
Thierschplatz 6
Lehel Carré
80538 Munich, Bavaria
Germany
Contact person: Thomas Gniadek, Partner
Company main phone: +49 (89) 2080776300
Company main fax: +49 (89) 2080776301
Website: https://www.simmons-simmons.com
Year founded: | 2013
|
Source of foundation: | Subsidiary |
Name of foundation source: | Simmons & Simmons, London |
No. of employees: |
Worldwide: 1500 |
Corporate description / mission:
Simmons & Simmons LLP operates as an international law firm. The company provides legal advices to asset management and investment funds, energy and infrastructure, financial institutions, life sciences, technology, media, and telecommunications sectors. The firm caters to the aerospace, consumer goods, energy and utilities, financial markets, pharmaceutical and biotechnology, real estate, construction, banking, finance, biotechnology, chemicals, communications, construction, and shipping industries.
State of ownership: Private / independent
Headquarters: HQ: No
Categorization
Sector: |
- Professional Services and Consulting
|
Business model: |
- Service company
- Subsidiary
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Collaborations & Clients
Client portfolio (as relevant):
M&A:
LEO Pharma
on its $1bn acquisition of Warner
Chilcott’s dermatology franchise
Ascendis Pharma
on its first major deal concerning
its proprietary TransCon Linker and
Hydrogel carrier technology, following
an auction process involving share sale
and licensing structures
R-Pharm Group
on the acquisition of a Pfizer production
plant in Germany
Rothschild and J.P.Morgan Cazenove
as joint sponsors, and Rothschild
as financial adviser, to BTG plc in
connection with its acquisition of
Biocompatibles International plc
Santen Pharmaceutical
on the acquisition of the majority stake
in France-based Novagali Pharma
Shareholders of Specifar
Pharmaceuticals
on the US$562m acquisition of the
company by Watson Pharmaceuticals
Inc
Sinochem
on an agreement with Netherlands
based DSM Anti-Infectives, to form
a 50/50 global anti-infectives joint
venture
ECM:
Amsterdam Molecular Therapeutics
on its successful €14.3m equity raising
Circassia Pharmaceuticals
the syndicate of underwriting banks on
Circassia’s £581m IPO on the London
Main Market in March 2014, London’s
largest biotech flotation for decades
Cryo-Save
on the secondary listing of the largest
adult stem cell storage bank in Europe
and its shares on Euronext Amsterdam
by NYSE Euronext (alongside the
company’s listing on AIM)
Kempen & Co and Petercam
on the successful €12m equity raising
by Euronext Amsterdam listed biotech
company Pharming Group N.V.
NetScientific plc
on its £30m placing and AIM IPO
Union MedTech plc
on its acquisition of Rex Bionics Limited
and £25.7m Placing and AIM IPO
Venture Life Group plc
on its acquisition of Biokosmes and £5m
Placing and AIM IPO